Biotech | March 16, 2022
Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
100% efficacy against severe Covid-19 disease and hospitalizations
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Subscribe To Our Newsletter & Stay Updated
